Sorafenib and sunitinib effectively inhibit various tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT3), KIT, and RET, suppressing tumor growth and angiogenesis by inhibiting VEGFR2/3 and PDGFRβ. This evidence concerns the gene KDR and neoplasm.